— Exact Sciences Corp. (NASDAQ: EXAS)
reported Q4 2019 earnings of $0.54 per share, vs. a loss of $0.35 expected.
— Total revenues were $295.6 million, vs. $283 million
expected.
— Screening revenues increased 60% to $229.4 million.
— Cologuard test volume rose 63% to 477,000.
— Average Cologuard recognized revenue per test was $481.
— Average Cologuard cost per test was $123.
— Precision Oncology proforma revenue increased 14% to
$119.1 million.
— FY2020 consolidated revenue is expected to be $1.61-1.64
billion.
— FY2020 Screening revenue is expected to be $1.125-1.15
billion.
— FY2020 Precision Oncology revenue is expected to be $485-495
million.
— EXAS shares gained 1.2% immediately following the
announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.